Clinical Activity of Selpercatinib in RET-mutant Pheochromocytoma.

Barbara Deschler-BaierBhavana KondaErminia MassarelliMimi I HuLori J WirthXiaojian XuJennifer WrightRoderick J Clifton-Bligh

Published in: The Journal of clinical endocrinology and metabolism (2024)

These data support selpercatinib as an effective therapy against RET-mutant pheochromocytoma, adding to the diversity of RET-activated tumor types that may benefit from targeted RET inhibition.

Keyphrases

wild type
electronic health record
big data
mesenchymal stem cells
drug delivery
cell therapy